scholarly journals Actinobacteria and Myxobacteria—Two of the Most Important Bacterial Resources for Novel Antibiotics

2016 ◽  
pp. 273-302 ◽  
Author(s):  
Wiebke Landwehr ◽  
Corinna Wolf ◽  
Joachim Wink
Keyword(s):  
Novel Antibiotics

Investigation of interspecies interactions between marine micromonosporaceae for identification of novel antibiotics

Planta Medica ◽  
2015 ◽  
Vol 81 (11) ◽  
Author(s):  
N Adnani ◽  
E Vazquez-Rivera ◽  
S Adibhatla ◽  
GA Ellis ◽  
D Braun ◽  
...  
Keyword(s):  
Interspecies Interactions ◽  
Novel Antibiotics

Novel Antibiotics from Marine Sources

2011 ◽  
Vol 4 (3) ◽  
pp. 1446-1461 ◽  
Author(s):  
E.A. Martis ◽  
G M Doshi ◽  
G V Aggarwal ◽  
P P Shanbhag
Keyword(s):  
Pharmaceutical Industry ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Drug Resistant Bacteria ◽  
Terrestrial Life ◽  
New Antibiotics ◽  
Antibiotic Compounds ◽  
New Generation ◽  
Novel Antibiotics ◽  
Untapped Resource

With the emergence of newer diseases, resistant forms of infectious diseases and multi-drug resistant bacteria, it has become essential to develop novel and more effective antibiotics. Current antibiotics are obtained from terrestrial life or made synthetically from intermediates. The ocean represents virtually untapped resource from which novel antibiotic compounds can be discovered. It is the marine world that will provide the pharmaceutical industry with the next generation of antibiotics. Marine antibiotics are antibiotics obtained from marine organisms. Scientists have reported the discovery of various antibiotics from marine bacteria (aplasmomycin, himalomycins, and pelagiomycins), sponges (Ara C, variabillin, strobilin, ircinin-1, aeroplysin, 3,5-dibromo-4-hydroxyphenylacetamide), coelenterates (asperidol and eunicin), mollusks (laurinterol and pachydictyol), tunicates (geranylhydroquinone and cystadytins), algae (cycloeudesmol, aeroplysinin-1(+), prepacifenol and tetrabromoheptanone), worms (tholepin and 3,5-dibromo-4-hydroxybezaldehyde), and actinomycetes (marinomycins C and D). This indicates that the marine environment, representing approximately half of the global diversity, is an enormous resource for new antibiotics and this source needs to be explored for the discovery of new generation antibiotics. The present article provides an overview of various antibiotics obtained from marine sources.

scholarly journals A novel chemical biology and computational approach to expedite the discovery of new-generation polymyxins against life-threatening Acinetobacter baumannii

2021 ◽  
Author(s):  
Xukai Jiang ◽  
Nitin A. Patil ◽  
Mohammad A. K. Azad ◽  
Hasini Wickremasinghe ◽  
Heidi Yu ◽  
...  
Keyword(s):  
Public Health ◽  
Chemical Biology ◽  
Multidrug Resistant ◽  
Computational Approach ◽  
Gram Negative Bacteria ◽  
Global Public Health ◽  
Gram Negative ◽  
Life Threatening ◽  
New Generation ◽  
Novel Antibiotics

Multidrug-resistant Gram-negative bacteria have been an urgent threat to global public health. Novel antibiotics are desperately needed to combat these 'superbugs'.

scholarly journals Synergizing the potential of bacterial genomics and metabolomics to find novel antibiotics

2021 ◽  
Author(s):  
Fabian Panter ◽  
Chantal D. Bader ◽  
Rolf Müller
Keyword(s):  
Natural Products ◽  
Antimicrobial Resistance ◽  
Public Concern ◽  
Bacterial Genomics ◽  
Technological Developments ◽  
Novel Antibiotics

Antimicrobial resistance is a major public concern and novel antibiotics are largely based on natural products. We summarize recent analytical and genome based technological developments that gain increasing importance in the natural products field.

scholarly journals Dynamicins O, P and Q: Novel antibiotics related to dynemicin a isolation, characterization and biological activity.

1991 ◽  
Vol 44 (10) ◽  
pp. 1037-1044 ◽  
Author(s):  
MEGUMI MIYOSHI-SAITOH ◽  
NAOKO MORISAKI ◽  
YOSHIYUKI TOKIWA ◽  
SHIGEO IWASAKI ◽  
MASATAKA KONISHI ◽  
...  
Keyword(s):  
Biological Activity ◽  
Novel Antibiotics

scholarly journals Diagnosis Confirmation Model: A Value-Based Pricing Model for Inpatient Novel Antibiotics

2018 ◽  
Vol 46 (S1) ◽  
pp. 66-74 ◽  
Author(s):  
Ka Lum ◽  
Taimur Bhatti ◽  
Silas Holland ◽  
Mark Guthrie ◽  
Stephanie Sassman
Keyword(s):  
High Risk ◽  
Financial Incentives ◽  
Drug Resistant ◽  
Pricing Model ◽  
Pricing Mechanism ◽  
A Value ◽  
Novel Antibiotics

The Diagnosis Confirmation Model (DCM) includes a dual-pricing mechanism designed to support value-based pricing of novel antibiotics while improving the alignment of financial incentives with their optimal use in patients at high risk of drug-resistant infections. DCM is a market-based model and complementary to delinked models. Policymakers interested in stimulating antibiotic innovation could consider tailoring the DCM to their reimbursement systems and incorporating it into the suite of incentives to improve the economics of antibiotics.

Sign in / Sign up

Export Citation Format

Share Document